Literature DB >> 33725155

Stellate ganglion block combined with intra-arterial treatment: a "one-stop shop" for cerebral vasospasm after aneurysmal subarachnoid hemorrhage-a pilot study.

Marco Pileggi1, Pascal J Mosimann2, Maurizio Isalberti3, Eike Immo Piechowiak2, Paolo Merlani4,5, Michael Reinert6, Alessandro Cianfoni3,2.   

Abstract

PURPOSE: Delayed cerebral ischemia (DCI) is a frequent cause of morbidity and mortality in patients with cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (aSAH). Refractory CV remains challenging to treat and often leads to permanent deficits and death despite aggressive therapy. We hereby report the feasibility and safety of stellate ganglion block (SGB) performed with a vascular roadmap-guided technique to minimize the risk of accidental vascular puncture and may be coupled to a diagnostic or therapeutic cerebral angiography.
METHODS: In addition to a detailed description of the technique, we performed a retrospective analysis of a series of consecutive patients with refractory CV after aSAH that were treated with adjuvant roadmap-guided SGB. Clinical outcomes at discharge are reported.
RESULTS: Nineteen SGB procedures were performed in 10 patients, after failure of traditional hemodynamic and endovascular treatments. Each patient received 1 to 3 SGB, usually interspaced by 24 h. In 4 patients, an indwelling microcatheter for continuous infusion was inserted. First SGB occurred on average 7.3 days after aSAH. SGB was coupled to intra-arterial nimodipine infusion or balloon angioplasty in 9 patients. SGB was technically successful in all patients. There were no technical or clinical complications.
CONCLUSION: Adjuvant SGB may be coupled to endovascular therapy to treat refractory cerebral vasopasm within the same session. To guide needle placement, using a roadmap of the supra-aortic arteries may decrease the risk of complications. More prospective data is needed to evaluate the therapeutic efficacy, durability, and safety of SGB compared with the established standard of care.

Entities:  

Keywords:  Aneurysms; Stellate ganglion; Subarachnoid hemorrhage; Vasospasm

Year:  2021        PMID: 33725155     DOI: 10.1007/s00234-021-02689-9

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  18 in total

1.  Cervical sympathetic and stellate ganglion blocks.

Authors:  M Elias
Journal:  Pain Physician       Date:  2000-07       Impact factor: 4.965

2.  Protective effect of stellate ganglion block on delayed cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage.

Authors:  Na Hu; Yun Wu; Bai-Zhao Chen; Jin-Feng Han; Mai-Tao Zhou
Journal:  Brain Res       Date:  2014-08-13       Impact factor: 3.252

3.  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Authors:  R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Angelina Marr; Sébastien Roux; Neal Kassell
Journal:  Lancet Neurol       Date:  2011-06-02       Impact factor: 44.182

4.  Medical Treatment Failure for Symptomatic Vasospasm After Subarachnoid Hemorrhage Threatens Long-Term Outcome.

Authors:  Sureerat Suwatcharangkoon; Gian Marco De Marchis; Jens Witsch; Emma Meyers; Angela Velazquez; Cristina Falo; J Michael Schmidt; Sachin Agarwal; E Sander Connolly; Jan Claassen; Stephan A Mayer
Journal:  Stroke       Date:  2019-06-05       Impact factor: 7.914

5.  Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition?

Authors:  Jennifer A Frontera; Andres Fernandez; J Michael Schmidt; Jan Claassen; Katja E Wartenberg; Neeraj Badjatia; E Sander Connolly; Stephan A Mayer
Journal:  Stroke       Date:  2009-04-09       Impact factor: 7.914

6.  Cerebral vasospasm after subarachnoid hemorrhage: an update.

Authors:  R C Heros; N T Zervas; V Varsos
Journal:  Ann Neurol       Date:  1983-12       Impact factor: 10.422

7.  Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

Authors:  R Loch Macdonald; Neal F Kassell; Stephan Mayer; Daniel Ruefenacht; Peter Schmiedek; Stephan Weidauer; Aline Frey; Sebastien Roux; Alberto Pasqualin
Journal:  Stroke       Date:  2008-08-07       Impact factor: 7.914

8.  Milrinone-Associated Cardiomyopathy and Arrhythmia in Cerebral Vasospasm.

Authors:  Eva M Wu; Tarek Y El Ahmadieh; Benjamin Kafka; Matthew T Davies; Salah G Aoun; Jonathan A White
Journal:  World Neurosurg       Date:  2018-03-31       Impact factor: 2.104

9.  Fatal rupture of the intracranial carotid artery during transluminal angioplasty for vasospasm induced by subarachnoid hemorrhage. Case report.

Authors:  M E Linskey; J A Horton; G R Rao; H Yonas
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

10.  Stellate ganglion block for treatment of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage - A preliminary study.

Authors:  Virendra Jain; Girija P Rath; Hari H Dash; Parmod K Bithal; Rajendra S Chouhan; Ashish Suri
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.